Research
Hormonal
Obestatin, a peptide derived from the same gene as ghrelin, suppresses food intake and decreases body weight gain, acting as an anorexigenic counter-regulator to ghrelin.
Obestatin is a peptide derived from the same gene as ghrelin but has the opposite effect: it suppresses food intake and reduces body weight gain. It acts as a natural brake on appetite, balancing the hunger signals sent by ghrelin.
GoodSupportsHIGH confidence
Contrary to the appetite-stimulating effects of ghrelin, treatment of rats with obestatin suppressed food intake, inhibited jejunal contraction, and decreased body-weight gain... Thus, two peptide hormones with opposing action in weight regulation are derived from the same ghrelin gene and activate distinct receptors.
Why this rating
Based on specific studies (Zhang et al. 2005) cited in the review, showing clear effects in rat models.
Source
Ghrelin: a hormone regulating food intake and energy homeostasis
Mercedes Gil‐Campos et al. · British Journal Of Nutrition · 2006
DOI 10.1079/bjn20061787
narrative_reviewCited 217×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Ghrelin is an orexigenic hormone that stimulates food intake and reduces energy expenditure by activating NPY/AgRP neurons in the hypothalamus, acting in opposition to leptin.Strong
- Plasma ghrelin levels increase with fasting and decrease after meals, with levels being higher after diet-induced weight loss compared to gastric bypass surgery.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →